Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 10% vs ANDROID 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Reduction of intracranial pressure and cerebral edema,Promotion of diuresis in patients with acute renal failure (oliguric phase) or to prevent renal failure in certain conditions,Reduction of intraocular pressure in acute glaucoma,Enhancement of urinary excretion of toxic substances (e.g., in overdoses),Adjunct in dialysis or hemofiltration (off-label)
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Terminal half-life: 1.1–1.6 hours; prolonged to 6–36 hours in renal impairment
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Mannitol is not metabolized in the body. It is eliminated unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Renal: 90% as unchanged drug; <10% metabolized in liver to fructose and glucose; fecal: negligible
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Negligible (<2%); does not bind to plasma proteins
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
0.36–0.5 L/kg; distributes primarily in extracellular fluid, limited CNS penetration due to hydrophilic nature
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
IV: 100%; oral: negligible (<10%) due to poor absorption and osmotic diarrhea
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolality.
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
No specific Child-Pugh based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
0.25-1 g/kg intravenously as a 10% solution over 30-60 minutes, repeated every 6-8 hours as needed.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
Start at lower end of dosing range (0.25-0.5 g/kg) due to decreased renal function; monitor fluid and electrolyte balance closely.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
None
None
Use with caution in patients with congestive heart failure due to risk of pulmonary edema from fluid overload,Monitor serum electrolytes (especially sodium and potassium) and renal function during therapy,May cause acute kidney injury with excessive doses or pre-existing renal impairment,In patients with intracranial hemorrhage, avoid rapid reduction of intracranial pressure,May cause expansion of extracellular fluid volume leading to pulmonary edema in patients with compromised cardiac function
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Anuria due to severe renal disease,Severe pulmonary edema or congestion,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
Avoid high-sodium foods and salt substitutes to prevent electrolyte imbalance; maintain adequate fluid intake unless fluid restriction is advised; no specific food interactions, but monitor for changes in blood glucose if diabetic.
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with clinical use is low. Second trimester: Generally safe for short-term use when indicated (e.g., elevated intracranial pressure), but avoid prolonged exposure to prevent fetal dehydration or electrolyte imbalances. Third trimester: Use cautiously; osmotic diuresis may cause maternal hypovolemia, potentially reducing placental perfusion and leading to fetal distress.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Mannitol is excreted into breast milk in low concentrations (estimated M/P ratio <0.1) due to its high molecular weight and hydrophilicity. Oral bioavailability in infants is negligible, and no adverse effects have been reported. However, caution is advised if used repeatedly or in high doses, as theoretical risk of neonatal electrolyte imbalance exists.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
Pregnancy does not significantly alter the pharmacokinetics of mannitol. Standard adult dosing (0.25–2 g/kg as a 10% solution) is recommended, with adjustments based on renal function, volume status, and therapeutic response. Avoid excessive doses to prevent maternal volume overload and electrolyte disturbances.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
Administer via in-line filter to prevent crystallization; monitor serum sodium and osmolality closely to avoid hypernatremia and osmotic demyelination; ensure adequate urine output before use to avoid pulmonary edema; use with caution in patients with congestive heart failure or renal impairment; can cause transient volume expansion followed by diuresis.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
This medication may cause increased thirst and frequent urination.,Report any chest pain, difficulty breathing, or swelling of ankles/legs.,Avoid consuming salty foods to prevent fluid retention.,Do not stop taking without consulting your doctor.,Inform your doctor if you have kidney disease, heart failure, or are on a low-salt diet.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 10% vs ANDROID 10, answered by our medical review team.
MANNITOL 10% is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.. ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 10% and ANDROID 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 10% is: 0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.. The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 10% and ANDROID 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 10% is classified as Category A/B. Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with c. ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.